What were the primary drivers of the significant decline in earnings per share for Q1 2002?

The primary drivers were a substantial $262 million pre-tax adjustment to correct an understatement of Medicaid and prime vendor rebates, coupled with significant revenue declines from key products like Glucophage IR, Taxol, and Buspar due to generic competition and loss of exclusivity.

How did the DuPont Pharmaceuticals acquisition impact the company's financial performance in Q1 2002?

The acquisition contributed $411 million in sales during the first quarter of 2002. It bolstered the company's product portfolio, particularly in the Pharmaceutical and Other Healthcare segments, and its results are now included in the consolidated financial statements.

What is the company's strategy regarding wholesaler inventory levels, and what is the expected impact?

The company has observed increased domestic wholesaler inventories due to prior sales incentives. To align inventory levels with market demand, they are reducing shipments, which is expected to negatively impact sales and earnings by approximately $0.40 per diluted share over the next four quarters, starting from Q2 2002.

How did the company's investment in ImClone Systems evolve in Q1 2002?

The commercialization agreement for Erbitux with ImClone Systems was revised in March 2002. Bristol-Myers Squibb paid $140 million, expensing $112 million as acquired in-process R&D and adding $28 million to its equity investment. The total equity investment in ImClone was $509 million as of March 31, 2002, with the company monitoring it for potential impairment.

BRISTOL MYERS SQUIBB CO 10-Q Quarterly Report Q1 FY2002

Summary

Bristol-Myers Squibb Company reported a significant decrease in net earnings for the first quarter of 2002 compared to the same period in 2001, largely due to a substantial adjustment for underestimated Medicaid and prime vendor rebates and the loss of exclusivity for key products. Net sales also declined, impacted by the rebate adjustment, generic competition, and a strategic reduction in wholesaler inventory. Despite these headwinds, the company saw growth in key products like Plavix and Pravachol, and the acquisition of DuPont Pharmaceuticals continued to contribute to sales, particularly in the Other Healthcare segment. The company is navigating patent expirations and investing in research and development to bolster its future product pipeline.

Key Highlights

1Net sales decreased by 13% to $4.08 billion in Q1 2002 compared to $4.69 billion in Q1 2001, primarily impacted by a $262 million pre-tax adjustment for Medicaid and prime vendor rebates and generic competition.
2Net earnings fell sharply to $585 million ($0.30 per diluted share) in Q1 2002 from $1.34 billion ($0.68 per diluted share) in Q1 2001.
3The company experienced significant declines in sales for products facing generic competition, including Glucophage IR, Taxol, and Buspar, with combined sales dropping from $1.62 billion in Q1 2001 to $150 million in Q1 2002 (excluding the rebate adjustment).
4Key products showed strong growth: Pravachol sales increased 7% to $542 million, and Plavix sales surged 29% to $384 million, benefiting from expanded indications.
5The acquisition of DuPont Pharmaceuticals, completed in late 2001, contributed $411 million to Q1 2002 sales, primarily within the Pharmaceutical and Other Healthcare segments.
6Operating cash flow was negative $1.086 billion in Q1 2002, a significant decrease from positive $869 million in Q1 2001, largely due to substantial income tax payments related to prior divestitures.
7The company adopted SFAS No. 142 on January 1, 2002, eliminating the amortization of goodwill, which previously amounted to $19 million in Q1 2001.

BRISTOL MYERS SQUIBB CO Quarterly Report for Q1 Ended Mar 31, 2002

Summary

Key Highlights

Frequently Asked Questions